Biomarker in Drug Discovery
Biomarker analysis can be performed at every stage of drug R&D using cell culture, serum, plasma, urine, tissue extracts, etc. The samples are examined to analyze patterns of biomarkers that correlate with progression of disease or therapy as well as metabolic and
toxicity indicators.
HDB provides integrated biomarker services, including biomarker discovery, gene expression profiling, microRNA detection and profiling, SNP genotyping, signaling and metabolite biomarker profiling, to researchers around the world. Besides traditional western-blot and ELISA, our biomarker services utilize a broad range of cutting-edge technologies for both single and multiplex assay platforms, such as qRT-PCR, Meso Scale
Discovery (MSD) Multi-Array detection, Flow Cytometry and cytometric bead array, etc.
The Latest Generation of Auto Patch Clamp Platform Launched at HDB
----------------------
WuXi Biology/HD Biosciences Presented at Webinar of "New Technologies for Target Discovery and Validation"
----------------------
HD Biosciences Merges with WuXi AppTec
HD Biosciences (China) Co.,Ltd
590 Ruiqing Road
Zhangjiang East Campus, Pudong, Shanghai 201201,
P.R.China
Tel: +86 (21) 5116 3700
Fax: +86 (21) 5116 3766
SERVICES
|
THERAPEUTIC AREAS
|
NEWS & EVENTS